The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1346
Natazia - A New Oral Contraceptive
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved the marketing of Natazia (Bayer), a 4-phase oral contraceptive containing the estrogen estradiol valerate and the progestin dienogest, both used for the first time in the US for this indication.

ORAL CONTRACEPTIVES — Most oral contraceptives available in the US are a combination of the synthetic estrogen ethinyl estradiol and a progestin. Monophasic oral contraceptives contain fixed doses of estrogen and progestin in each active pill. Multiphasic oral contraceptives vary the dose of one or both hormones during the pill cycle and generally have a lower total hormone dose per cycle.

DOSAGE — The recommended dosage of this new combination includes an estrogen step-down and a progestin step-up; days 1-2: estradiol valerate 3 mg alone; days 3-7: estradiol valerate 2 mg/dienogest 2 mg; days 8-24: estradiol valerate 2 mg/dienogest 3 mg; days 25-26: estradiol valerate 1 mg ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Natazia - A New Oral Contraceptive
Article code: 1346d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian